Nanoparticulate and controlled release compositions comprising cyclosporine
US7825087B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2006 |
| Grant date | Nov 2, 2010 |
| Priority date | — |
| Expiry date | Nov 5, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5078
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.